CASI Pharmaceuticals (CASIF) Gross Margin (2022 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Gross Margin came in at 51.14% in Q4 2025, up 2697.0% YoY from 1.83% in Q4 2024, and up 122.72% on a QoQ basis from 22.96% in Q3 2025.
CASI Pharmaceuticals (CASIF) Gross Margin (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 4 years of Gross Margin data on file, last reported at 51.14% in Q4 2025.
- Quarterly Gross Margin rose 2697.0% year-over-year to 51.14% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 48.65% (up 959.0% YoY) and the FY2025 annual result came in at 48.65%, up 959.0% from the prior year.
- Gross Margin grew to 51.14% in Q4 2025, from 22.96% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 107.1% in Q4 2022 to a low of 22.96% in Q3 2025.
- A 4-year average of 55.13% and a median of 58.21% in 2022 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2023 — Gross Margin sank 4805 bps — and 2025, when it surged 2697 bps.
- Tracing CASIF's Gross Margin over 4 years: stood at 107.1% in 2022, then plunged by 45 bps to 59.05% in 2023, then sank by 59 bps to 24.17% in 2024, then jumped by 112 bps to 51.14% in 2025.
- The last three Gross Margin figures came in at 51.14% (Q4 2025), 22.96% (Q3 2025), and 49.29% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 51.14% |
| Sep 30, 2025 | 22.96% |
| Jun 30, 2025 | 49.29% |
| Mar 31, 2025 | 58.00% |
| Dec 31, 2024 | 24.17% |
| Sep 30, 2024 | 51.91% |
| Jun 30, 2024 | 51.95% |
| Mar 31, 2024 | 52.98% |
| Dec 31, 2023 | 59.05% |
| Sep 30, 2023 | 58.72% |
| Jun 30, 2023 | 59.41% |
| Mar 31, 2023 | 59.53% |
| Dec 31, 2022 | 107.10% |
| Sep 30, 2022 | 58.42% |
| Jun 30, 2022 | 58.75% |
| Mar 31, 2022 | 58.77% |